Company Information

  

Address: 100 COLLEGE STREET  
City: NEW HAVEN 
State: CT 
Zip Code: 06510 
Telephone: 203-272-2596 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company focused on serving patients with devastating and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. 3 -------------------------------------------------------------------------------- In our complement franchise, Soliris® is the first and only therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. In our metabolic franchise, we commercialize Strensiq® for the treatment of patients with Hypophosphatasia (HPP) and Kanuma® for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/20172.24NA62.63
06/20172.31NA52.67
03/20172.10NA57.73
12/20161.76NA69.52
09/20161.65NA74.27
06/20160.30NA389.20
03/20160.63NA220.98
12/20150.67NA284.70

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity0.06Total Liab/Total Assets0.34
Net Inc/Total Assets0.03Total Liab/Inv Cap0.37
Net Inc/Inv Cap0.03Total Liab/Comm Equity0.67
Pretax Inc/Net Sales0.19Interest Coverage Ratio6.94
Net Inc/Net Sales0.13Curr Debt/Equity0.02
Cash Flow/Net Sales0.35LTD/Equity0.36
SG&A/NetSales0.32Total Debt/Equity0.38
Asset Utilization   Liquidity  
Net Receivables Turnover5.21Quick Ratio2.68
Inventory Turnover0.78Current Ratio3.13
Inventory Day Sales0.00Net Rec/Curr Assets0.25
Net Sales/Work Cap1.76Inv/Curr Assets0.15
Net Sales/PP&E2.98  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 859.00 912.00 870.00 831.00
Cost of Goods Sold 157.00 84.00 69.00 68.00
Selling & Admin Exps 275.00 289.00 266.00 264.00
Operating Income 80.00 226.00 212.00 127.00
Interest Exp 25.00 24.00 24.00 25.00
Pretax Income 58.00 206.00 194.00 104.00
Other Income 3.00 4.00 6.00 2.00
Net Income Bef Extraordinary ... NA NA NA NA
Net Income 78.00 165.00 170.00 93.00

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 1,529.00 1,444.00 1,462.00 1,293.00
Receivables - Total 705.00 710.00 660.00 650.00
Inventories - Total 441.00 410.00 396.00 375.00
Total Current Assets 2,882.00 2,789.00 2,733.00 2,578.00
Net Property, Plant & Equipment 1,354.00 1,233.00 1,138.00 1,036.00
Total Assets 13,643.00 13,489.00 13,435.00 13,253.00
Liabilities        
Accounts Payable 738.00 613.00 607.00 572.00
Debt in Current Liabilities 167.00 167.00 167.00 167.00
Total Current Liabilities 972.00 856.00 837.00 823.00
Long-Term Debt 3,096.00 3,081.00 3,116.00 3,121.00
Total Liabilities 4,699.00 4,614.00 4,579.00 4,559.00
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings 2,212.00 2,134.00 1,969.00 1,818.00
Treasury Stock -1,440.00 -1,380.00 -1,209.00 -1,141.00
Total Stockholders' Equity 8,944.00 8,875.00 8,856.00 8,694.00
Total Liabilities and Stockholders' Equity 13,643.00 13,489.00 13,435.00 13,253.00

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities 270.00 280.00 308.00 383.00
Net Cash Provided by Investing Activities -171.00 -253.00 -495.00 115.00
Net Cash Provided by Financing Activities -95.00 -207.00 -69.00 -284.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20121,134.11254.821.28
12/20131,551.35252.901.27
12/20142,234.00657.003.26
12/20152,604.00144.000.67
12/20163,084.00399.001.76
Growth Rates28.4111.868.29

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17653213,78295.69




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.